Cargando…
TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is associated with very poor survival, making it the third and fourth leading cause of all cancer-related deaths in the USA and European Union, respectively. The tumor microenvironment (TME) in PDAC is highly immunosuppressive and desmoplastic, whi...
Autores principales: | Perez-Penco, Maria, Weis-Banke, Stine Emilie, Schina, Aimilia, Siersbæk, Majken, Hübbe, Mie Linder, Jørgensen, Mia Aaboe, Lecoq, Inés, Lara de la Torre, Lucia, Bendtsen, Simone Kloch, Martinenaite, Evelina, Holmström, Morten Orebo, Madsen, Daniel Hargbøl, Donia, Marco, Ødum, Niels, Grøntved, Lars, Andersen, Mads Hald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730419/ https://www.ncbi.nlm.nih.gov/pubmed/36600556 http://dx.doi.org/10.1136/jitc-2022-005491 |
Ejemplares similares
-
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells
por: Weis-Banke, Stine Emilie, et al.
Publicado: (2022) -
The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines
por: Weis-Banke, Stine Emilie, et al.
Publicado: (2020) -
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment
por: Bendtsen, Simone Kloch, et al.
Publicado: (2022) -
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2021) -
Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2022)